
Combination treatment with olaparib and ceralasertib shows promise in pediatric tumors with DNA replication stress or repair deficiencies.


coremsg

The novel ataxia telangiectasia–mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.

Novel ATR Inhibitor Shows Promise in Children With Tumors

novel-atr-inhibitor-shows-promise-in-pediatric-tumors


Novel ATR Inhibitor Shows Promise in Pediatric Tumors
